Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 4 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 6th Aug, paid: 2nd Oct more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -1.7%

FINANCIAL BRIEF: For the six months ended 30 June 2014, GlaxoSmithKline plc revenues decreased 15% to L11.17B. Net income decreased 34% to L1.32B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Pharmaceuticals R & D segment loss increase of 86% to L1.31B, Unallocated segment loss increase of 67% to L734M, Corpoate costs segment loss increase of 96% to L417M. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
A-
A-

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: 1,579 (+10.41% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +2.9% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
26 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 2 4 18 5 2

Named Brokers and Analysts
Jefferies & Company, Inc. Jeffrey Holford , Credit Suisse Jo Walton , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Bank Vontobel AG , First Global Kavita Thomas , Nomura Securities , Jefferies International Ltd , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone , Collins Stewart & Co , Mirabaud Securities Nicholas Turner , Davy , CA Cheuvreux Marcel Brand , Macquarie Research , Societe Generale Stephen McGarry , Erste Bank Stephan Lingnau , WestLB Equity Markets , Berenberg Alistair Campbell , DZ Bank , Oddo Securities , Helvea SA Odile Rundquist , Hamburger Sparkasse (HASPA) Marco Gunther , Kepler Cheuvreux Fabian Wenner, PhD , Charles Stanley Rae Ellingham , Cenkos Securities Navid Malik , Raymond James Euro Equities , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Matrix Corporate Capital LLP , Liberum Naresh Chouhan , Alphavalue Armelle Moulin , Beaufort Securities ,

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Directors: Andrew Witty (CEO) 49, Simon Dingemans (CFO) 50, Moncef Slaoui (CEX) 54, Deirdre Connelly (CEX) 53, Roger Connor (CEX) , Shah Abbas Hussain (CEX) 47, Patrick Vallance (CEX) , Emma Walmsley (CEX) , Daniel Troy (SVP) , Claire Thomas (SVP) , Christopher Gent (NEC) 65, Roy Anderson (NID) 66, Stephanie Burns (NID) 59, Stacey Cartwright (NID) 50, Tom de Swaan (NID) 68,

No. of Employees: 99,817 No. of Shareholders: 142,145


Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 4,849,530,949
Free Float 4.78bn (98.5%)
ISIN GB0009252882

Address 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Web http://www.gsk.com
Phone +44 20 80475000
Contact ()
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSK Quote
1429.5p
-5.0  -0.3%
Traded 5:06pm · Minimum 15 min delayed · NMS: 1.000k

Latest GSK News Announcements (delayed)

Upcoming GSK Events
Tuesday 9th September, 2014
GlaxoSmithKline PLC Investor and Analyst Event at the European Respiratory Society
Wednesday 22nd October, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Release
Thursday 7th May, 2015 (estimate)
GlaxoSmithKline PLC Annual Shareholders Meeting

Recent ↓
Wednesday 6th August, 2014
Dividend For GSK
Wednesday 6th August, 2014
Dividend For GSK.BA
Wednesday 23rd July, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Call
Wednesday 23rd July, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release
Tuesday 15th July, 2014
Codexis Inc Announces Technology Collaboration and License Agreement With GSK Conference Call
Monday 2nd June, 2014
GlaxoSmithKline at Jefferies Global Healthcare Conference
Thursday 22nd May, 2014
GlaxoSmithKline PLC United Way of Greater Philadelphia and Southern New Jersey Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
Thursday 22nd May, 2014
GlaxoSmithKline PLC Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
Wednesday 14th May, 2014
Pernix Therapeutics Holdings Inc Conference Call with GlaxoSmithKline to acquire the U.S rights to Treximet®
Wednesday 14th May, 2014
Dividend For GSK


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy GSK

Access GSK Analytics Now!

FREE TRIAL or TAKE THE TOUR